Advances in Penile Cancer Research from the Bench Side to the Patients
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 5931
Special Issue Editors
Interests: penile cancer; renal cell cancer; HPV-related cancers
Special Issue Information
Dear Colleagues,
Penile cancer is a rare and deadly cancer that affects more than 30,000 patients around the globe every year. Over the past two decades we have seen limited improvement in the clinical outcomes of patients with advanced penile cancer.
In this Special Issue we aim to highlight all advances, covering benchside to bedside efforts, that have been made in penile cancer, in hope of improving the clinical outcomes of patients with this rare and challenging cancer.
We aim to include papers focusing on advances in preclinical specific penile cancer models as well as molecular, viral, and immune pathways related to penile cancer oncogenesis that have led to our better understanding of the disease development.
We will also include papers highlighting advances in chemotherapies, vaccine, as well as immune-based and targeted therapies for patients with localized and advanced penile cancer. Papers highlighting advances in radiation and surgical therapies will be welcomed.
Finally, we will showcase research focused on patient-centered approaches with advances in patient-reported outcome and quality-of-life research.
Dr. Jad Chahoud
Dr. Philippe E. Spiess
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- penile cancer
- preclinical models and systems
- tumor–microenvironment interaction
- targeted therapies
- vaccine therapies
- immune-based therapies
- molecular pathways immune pathways
- clinical trials
- HPV oncogenesis
- patient-reported outcomes and quality of life
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.